Clinical Trials
12 trialsNCT04523857 2026-05-26
ABBY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05576896 2026-05-26
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT05365893 2026-05-22
PHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03598595 2026-05-14
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03825289 2026-05-14
THREAD
University of Utah
Phase 1 Terminated
NCT05036226 2026-05-13
COAST
Medical University of South Carolina
Phase 1/2 Recruiting
NCT04464759 2026-05-11
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2 Recruiting
NCT05842174 2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2 Recruiting
NCT01480154 2026-04-13
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05518110 2026-04-13
PaTcH
Cancer Trials Ireland
Phase 2 Terminated
NCT04841148 2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04132505 2026-04-06
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed